Efficacy and Safety of a Single Dose of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein: Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Atopic Dermatitis or with Chronic Pruritus
Share This Story, Choose Your Platform!
About the Author: attovia
